Global Orphan and Rare Dermatological Diseases Market Report 2018: First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa - ResearchAndMarkets.com
The "Orphan and Rare Dermatological Diseases - First-in-Class Therapies Demonstrate Potential Disease-Modifying Effects in Areas of High Unmet Need Such as Epidermolysis Bullosa" report has been added to ResearchAndMarkets.com's offering.
This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key indications, Systemic Sclerosis (Scleroderma), Alopecia, Epidermolysis Bullosa (EB), Pemphigus Vulgaris, Vitiligo and Cutaneous Lupus Erythematosus (CLE), as these conditions have the largest pipelines within the therapy area.
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from the rare diseases such as systemic sclerosis (scleroderma), an autoimmune disorder, to very common conditions such as acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation. Many of these disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled.
In particular, disease visibility can have a profoundly negative impact on patient confidence. As many dermatological conditions are chronic in nature, these symptoms can also increase the risk of developing psychosocial comorbidities - such as depression and anxiety - over time.
Unmet need within the Orphan and Rare Dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors. Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across Orphan and Rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.
- There is a strong need for innovative new therapies across the orphan and rare dermatology market. How are orphan and rare dermatological diseases currently managed? What are the greatest unmet needs within this market?
- There are 262 pipeline products in development across all orphan and rare dermatological diseases. How does the composition of the pipeline compare with that of the existing market? Which molecular targets are most frequently acted upon by pipeline drugs? How do products in development for the key indications differ in terms of molecule type?
- Over one-third of pipeline products with a disclosed molecular target are first-in-class. How does the proportion of first-in-class products in development differ in terms of stage of development, molecule type and molecular target class? Which are the most promising first-in-class targets?
- The deals landscape has become more active in recent years. Which indications and products have attracted the highest deal values?
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
3 The Case for Innovation
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation
6 Signalling Network, Disease Causation and Innovation Alignment
7 First-in-Class Molecular Target Evaluation
8 Strategic Consolidations
For more information about this report visit https://www.researchandmarkets.com/research/z3mt66/global_orphan_and?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005627/en/